🏛️ Verified NIH Record • Updated 2026-06-16

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies (NCT01652092)

🔵 Active, Not Recruiting Observational / Diagnostic 💊 Investigational Drug / Biologic Sponsor: Masonic Cancer Center, University of Minnesota

🩺 Plain-English Summary (8th-Grade Level)

This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (28 items) and avoid the listed exclusions (4 items).

Location: Masonic Cancer Center, University of Minnesota — Minneapolis, Minnesota

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria
  • pregnant or breastfeeding
  • active, uncontrolled infection and/or HIV positive
  • acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on biopsy

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

  • Masonic Cancer Center, University of Minnesota — Minneapolis, Minnesota

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗